JJDC, formed in 1973, makes private equity investments in healthcare companies, including pharmaceuticals, biotechnology, medical devices, diagnostics, and consumer products. They provide long-term support to their portfolio companies, leveraging the resources of Johnson & Johnson for discovery, clinical development, manufacturing, and commercialization. JJDC plays a strategic role in identifying new business opportunities and market trends, both within and outside of Johnson & Johnson's traditional portfolio. They have invested in companies such as CVRx, Grail, Fusion Pharmaceuticals, and have exited investments in NovoCure, Nevro, Inspire Medical Systems, and others.